Two-thirds of Americans are obese or overweight, according to the Centers for Disease Control and Prevention.
The US Food and Drug Administration plans on reviewing three new anti-obesity drugs by the end of 2010. The FDA will announce its decision on two of these drugs within the next few months.
LGM Pharma is a US based supplier of the following APIs (Active Pharmaceutical Ingredients) for research and development purposes:
- Topiramate – which is combined with Phentermine to create the obesity drug “Qnexa”.
- Bupropion and Naltrexone – combine to create the drug “Contrave”.
- Lorcaserin – available on LGM Pharma’s website.
The combination of the drugs Phentermine and Topiramate (trade name Qnexa). It is an investigational medication for the treatment of obesity and related conditions such as type 2 diabetes. It has been found to lower blood pressure and cholesterol. FDA’s advisory committee voted not to approve Qnexa due to the potential side effects of the drug.
Another one of the anti-obesity drugs is a combination of the two approved drugs Bupropion and Naltrexone. In clinical trials, patients taking the sustained-release formulation (trade name Contrave) combined with diet and exercise, lost more weight than patients taking a placebo following the same diet and exercise program.
Lorcaserin is different from the previous two anti-obesity drugs under review in that it is a new molecule, not a combination of existing, approved medications. FDA’s advisory panel will meet on Sept. 16, 2010, to discuss Lorcaserin, and Oct. 22, 2010, is the PDUFA date (one week before Qnexa).
*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.